Does PI-RADS 5 automatically mean high-risk prostate cancer?

No. PI-RADS 5 means MRI suspicion for clinically significant cancer is very high. A formal clinical risk group needs PSA, clinical stage, biopsy Grade Group, and biopsy involvement.

Favorable, Unfavorable, or High Risk?

Q: Are Gleason 3+4 and 4+3 equivalent?

No. Both total 7, but 3+4 is Grade Group 2 because pattern 3 predominates, while 4+3 is Grade Group 3 because pattern 4 predominates.

Q: Can the same Grade Group belong to different clinical risk groups?

Yes. In the AUA/ASTRO localized prostate cancer framework, Grade Group 2 can be favorable intermediate, unfavorable intermediate, or part of a high-risk picture depending on PSA, clinical stage, and biopsy involvement.

Clinical risk group

Clinical risk groups include , intermediate ( or ), and . These groups combine PSA, biopsy findings, and clinical stage to estimate how likely prostate cancer is to progress or return after treatment. They help guide decisions about surveillance, treatment, and staging tests. Risk group is not a survival percentage. Individual outcomes depend on the cancer’s features, treatment, and the patient’s age and overall health.

AUA/ASTRO clinical risk groups

Group	AUA/ASTRO criteria
	PSA <10 ng/mL AND Grade Group 1 AND clinical stage T1 to T2a.
Lower likelihood of progression; active surveillance is often preferred.
	Grade Group 1 AND PSA 10 to <20 AND T1 to T2a AND <50% positive biopsy cores; OR Grade Group 1 AND PSA <10 AND T2b-c AND <50% positive biopsy cores; OR Grade Group 2 AND PSA <10 AND T1 to T2a AND <50% positive biopsy cores.
More favorable intermediate-risk disease; selected patients may consider surveillance as well as treatment.
	Grade Group 1 with PSA 10 to <20 AND T2b-c, OR Grade Group 2 with PSA 10 to <20 and/or T2b-c and/or ≥50% positive biopsy cores, OR Grade Group 3 with PSA <20.
Greater progression or recurrence risk; treatment is generally favored for patients likely to benefit.
	PSA ≥20 ng/mL OR Grade Group 4 to 5 OR clinical stage T3.
Higher progression or recurrence risk; staging and more intensive treatment planning are often needed.

Favorable versus unfavorable intermediate: one change at a time

Gleason	PSA	Clinical stage	Biopsy involvement	Result
3+4	6	T1c	2/12 systematic cores positive	Favorable intermediate
	6	T1c	2/12 systematic cores positive	Unfavorable intermediate
3+4		T1c	2/12 systematic cores positive	Unfavorable intermediate
3+4	6	T1c	systematic cores positive	Unfavorable intermediate

Prostate Cancer Risk Assistant

Use PSA, biopsy findings, and clinical stage to identify the AUA/ASTRO risk group for newly diagnosed, clinically localized prostate cancer.

Inputs

Scope check

PSA, ng/mL

Grade Group

Clinical T stage

Use the clinical T stage documented by the treating clinician. For this AUA risk classification, it is based on the digital rectal examination (DRE), not the amount of tumor visible on MRI.

Risk grouping uses PSA, biopsy findings, and clinical stage. MRI is not required to assign the group.

Systematic biopsy cores

Positive Total

Targeted biopsy counting

No targeted biopsy performed. Targeted biopsy performed; lesion counts available. Targeted biopsy performed; lesion counts unavailable.

AUA/ASTRO counts multiple cores from the same targeted lesion as one core for percent positive cores.

Methodology and source notes

The Risk Assistant uses AUA/ASTRO Table 3 criteria from the 2022 clinically localized prostate cancer guideline. Percent positive biopsy cores is the number of cores containing cancer divided by total cores obtained; multiple targeted cores from the same lesion count as one positive or negative core. The 2026 amendment imaging summary used here states: do not routinely stage asymptomatic low- or favorable intermediate-risk patients for metastasis; stage unfavorable intermediate- and high-risk patients with PSMA PET or conventional cross-sectional imaging plus bone scan. The official 2026 amendment link is retained above; direct full-text access was restricted in this environment, so verify the exact amendment text directly for formal policy use. This tool does not generate imaging orders.

Test yourself

0/3 correct

1. Does PI-RADS 5 automatically mean high-risk cancer?

2. Are Gleason 3+4 and 4+3 equivalent?

3. Can the same Grade Group belong to different clinical risk groups?

Sources

About this article This educational article was written by Nicholas H. Shaheen, MD for the Prostate MRI Toolkit. It is intended for teaching and reference, is not peer reviewed, and should not replace local practice standards, institutional protocols, or formal society guidelines. Last updated: October 10, 2026